BR9807873A - Vacinas de flavivìrus quiméricos - Google Patents

Vacinas de flavivìrus quiméricos

Info

Publication number
BR9807873A
BR9807873A BR9807873A BR9807873A BR9807873A BR 9807873 A BR9807873 A BR 9807873A BR 9807873 A BR9807873 A BR 9807873A BR 9807873 A BR9807873 A BR 9807873A BR 9807873 A BR9807873 A BR 9807873A
Authority
BR
Brazil
Prior art keywords
flavivir
vaccines
chimeric
yellow fever
protein
Prior art date
Application number
BR9807873A
Other languages
English (en)
Inventor
Thomas J Chambers
Thomas P Monath
Farshad Guirakhoo
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oravax Inc filed Critical Oravax Inc
Publication of BR9807873A publication Critical patent/BR9807873A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MéRICOS"<D>. Um vírus quimérico atenuado, infeccioso, vivo, contendo um vírus da febre amarela, no qprM-E é deletada, truncada, ou mutada, de modo que a proteína prM-E funcional não seja expressa, e, integrada no genoma do vírus da febre amarela, uma seq³ência de nucleotídeos codificando uma proteínexpressa.
BR9807873A 1997-02-28 1998-03-02 Vacinas de flavivìrus quiméricos BR9807873A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80744597A 1997-02-28 1997-02-28
US766498A 1998-01-15 1998-01-15
PCT/US1998/003894 WO1998037911A1 (en) 1997-02-28 1998-03-02 Chimeric flavivirus vaccines

Publications (1)

Publication Number Publication Date
BR9807873A true BR9807873A (pt) 2000-03-21

Family

ID=26677253

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807873A BR9807873A (pt) 1997-02-28 1998-03-02 Vacinas de flavivìrus quiméricos

Country Status (21)

Country Link
EP (3) EP1625852B1 (pt)
JP (2) JP4504464B2 (pt)
KR (1) KR100517323B1 (pt)
CN (1) CN1187088C (pt)
AT (2) ATE468858T1 (pt)
AU (1) AU740961B2 (pt)
BR (1) BR9807873A (pt)
CA (1) CA2282790C (pt)
CZ (1) CZ300172B6 (pt)
DE (2) DE69830579T2 (pt)
DK (2) DK1625852T3 (pt)
ES (2) ES2345614T3 (pt)
HK (1) HK1025743A1 (pt)
HU (1) HU228705B1 (pt)
IL (4) IL131600A0 (pt)
NO (1) NO329693B1 (pt)
NZ (1) NZ337522A (pt)
PL (1) PL192957B1 (pt)
PT (2) PT977587E (pt)
RU (1) RU2209082C2 (pt)
WO (1) WO1998037911A1 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
IL139844A0 (en) 1998-06-04 2002-02-10 Us Gov Health & Human Serv Nucleic acid vaccines for prevention of flavivirus infection
US7009044B1 (en) * 1999-06-04 2006-03-07 The United States Of America As Represented By The Department Of Health And Human Services HCV/BVDV chimeric genomes and uses thereof
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
EP1978027B1 (en) * 2000-02-10 2012-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Full-length infectious cDNA clones of tick borne flavivirus
EP3000477A1 (en) 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
AU2007202304B2 (en) * 2001-04-04 2010-03-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Nucleic acid vaccines for prevention of flavivirus infection
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US20030232324A1 (en) 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
EP1399183B1 (en) * 2001-05-31 2010-06-30 Novartis Vaccines and Diagnostics, Inc. Chimeric alphavirus replicon particles
CA2448971C (en) 2001-06-01 2013-11-26 Acambis, Inc. Chimeric flavivirus vectors
US6682883B1 (en) * 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
EP1441761B1 (en) * 2001-10-19 2007-04-18 Acambis, Inc. Methods of preventing and treating flavivirus infection in animals
US20060204523A1 (en) * 2001-11-26 2006-09-14 Khromykh Alexander A Flavivirus vaccine delivery system
US7459160B2 (en) 2002-01-15 2008-12-02 Acambis Inc. Chimeric flaviviruses
ES2427139T3 (es) * 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
EP1546176A4 (en) * 2002-07-19 2006-01-11 Univ Texas METHODS AND COMPOSITIONS ASSOCIATED WITH ALTERED YELLOW FEVER VIRUS STEM
CA2505942C (en) 2002-11-15 2012-03-13 Acambis, Inc. West nile virus vaccine
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CN1304579C (zh) * 2003-07-21 2007-03-14 上海天甲生物医药有限公司 重组的以黄热病病毒为载体的疫苗
WO2005040390A1 (fr) * 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. Vaccin recombine utilisant le virus de la fievre jaune comme vecteur
CN101018860B (zh) * 2004-07-12 2013-02-27 美国天甲生物医药有限公司 黄病毒疫苗
AU2005295438B2 (en) 2004-10-20 2012-07-05 Sanofi Pasteur Biologics, Llc Vaccines against Japanese encephalitis virus and West Nile virus
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7749734B2 (en) 2004-12-24 2010-07-06 The Research Foundation For Microbial Diseases Of Osaka University Attenuated chimeric flavivirus bearing attenuated Japanese encephalitis virus gene as backbone
CN103031279B (zh) 2005-04-24 2015-11-18 赛诺菲巴斯德生物制药有限责任公司 重组黄病毒疫苗
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
BRPI0504945B8 (pt) * 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP3018142A1 (en) 2006-06-06 2016-05-11 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
BRPI0714721A2 (pt) 2006-07-14 2013-04-24 Sanofi Pasteur Biologics Co construÇço de vacinas de vÍrus recombinante por inserÇço direta mediada por transpàson de determinantes imunolàgicos estranhos em proteÍnas de vÍrus vetorial
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
WO2008057550A2 (en) 2006-11-07 2008-05-15 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
WO2008094674A1 (en) * 2007-01-31 2008-08-07 Sanofi Pasteur Biologics Co. Recombinant bicistronic flavivirus vectors
WO2008100464A1 (en) * 2007-02-09 2008-08-21 Sanofi Pasteur Biologics Co. Viral vectors and methods of use
JP5689687B2 (ja) 2008-03-05 2015-03-25 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ アジュバント含有ワクチン組成物の安定化方法
US8815564B2 (en) * 2008-03-14 2014-08-26 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
MX2015000446A (es) 2012-07-24 2015-03-12 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
AU2013327265A1 (en) 2012-10-03 2015-04-30 Sanofi Pasteur Vaccination against Japanese encephalitis, measles, mumps and rubella
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
PL3539565T3 (pl) 2013-03-15 2023-09-25 Takeda Vaccines, Inc. Kompozycje i sposoby dla konstruktów chimerycznych wirusa dengi w szczepionkach
CN105246506A (zh) 2013-06-21 2016-01-13 默沙东公司 登革病毒疫苗组合物及其使用方法
CN103352029A (zh) * 2013-07-29 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 一种乙脑/森林脑炎嵌合病毒及其应用
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
SG11201704942QA (en) 2014-12-22 2017-07-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
CN105400799B (zh) * 2015-12-22 2018-12-28 成都生物制品研究所有限责任公司 一种乙脑/黄热嵌合病毒及其制备方法和应用
BE1024160A9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
GB201716307D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Chimeric yellow fever zika virus strain
WO2019212312A1 (ko) * 2018-05-04 2019-11-07 에스케이바이오사이언스 주식회사 키메라 지카바이러스 백신
WO2020051328A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Assay for determining antibody response to dengue virus
MX2021002586A (es) 2018-09-05 2021-06-08 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administracion de esta.
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
GB201814563D0 (en) * 2018-09-07 2018-10-24 Univ Leuven Kath Chimeric flavivirus lyssavirus vaccines
AU2020331884A1 (en) 2019-08-16 2022-03-03 Takeda Vaccines, Inc. Methods for preventing dengue and Hepatitis A
EP4110381A1 (en) 2020-02-27 2023-01-04 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
CN113215116B (zh) * 2021-05-11 2022-07-19 中国科学院动物研究所 基于朝阳病毒载体的嵌合病毒、疫苗及其应用
CN117751183A (zh) * 2021-05-27 2024-03-22 迈凯恩技术有限公司 使用假病毒的抗体依赖性感染增强反应的评价方法
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91304A0 (en) * 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
ATE186744T1 (de) * 1991-09-19 1999-12-15 Us Health Chimäre und/oder wachstumsgehemmte flaviviren

Also Published As

Publication number Publication date
PT977587E (pt) 2005-10-31
NO994185D0 (no) 1999-08-27
PL335481A1 (en) 2000-04-25
PT1625852E (pt) 2010-08-27
HUP0002139A3 (en) 2001-10-29
KR20000075830A (ko) 2000-12-26
HK1025743A1 (en) 2000-11-24
JP2001514622A (ja) 2001-09-11
JP2010057496A (ja) 2010-03-18
DE69830579T2 (de) 2006-05-04
CA2282790A1 (en) 1998-09-03
ES2244050T3 (es) 2005-12-01
KR100517323B1 (ko) 2005-09-27
ATE468858T1 (de) 2010-06-15
DE69830579D1 (de) 2005-07-21
EP0977587A4 (en) 2000-08-02
RU2209082C2 (ru) 2003-07-27
EP1625852B1 (en) 2010-05-26
HU228705B1 (en) 2013-05-28
EP0977587B1 (en) 2005-06-15
IL131600A0 (en) 2001-01-28
HUP0002139A2 (hu) 2000-10-28
NZ337522A (en) 2001-02-23
JP4504464B2 (ja) 2010-07-14
CA2282790C (en) 2011-04-19
IL193170A0 (en) 2009-02-11
IL193170A (en) 2015-08-31
IL207516A0 (en) 2010-12-30
AU6443198A (en) 1998-09-18
EP1625852A1 (en) 2006-02-15
IL207517A0 (en) 2010-12-30
CZ300172B6 (cs) 2009-03-04
CN1253506A (zh) 2000-05-17
EP0977587A1 (en) 2000-02-09
ES2345614T3 (es) 2010-09-28
CN1187088C (zh) 2005-02-02
NO329693B1 (no) 2010-12-06
ATE297757T1 (de) 2005-07-15
NO994185L (no) 1999-10-27
CZ306499A3 (cs) 2000-01-12
WO1998037911A1 (en) 1998-09-03
EP2251036A1 (en) 2010-11-17
DK0977587T3 (da) 2005-10-17
PL192957B1 (pl) 2006-12-29
AU740961B2 (en) 2001-11-15
DE69841690D1 (de) 2010-07-08
DK1625852T3 (da) 2010-09-20

Similar Documents

Publication Publication Date Title
BR9807873A (pt) Vacinas de flavivìrus quiméricos
TR200100350T2 (tr) Newcastle hastalığı virüsü, enfeksiyon klonları, aşılar ve diyagnostik testler.
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31&#39; dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
HUP9903829A3 (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
ATE386106T1 (de) Rekombinante poxvirus-cytomegalovirus zusammensetzungen und ihre verwendung
DK0386734T3 (da) Immunogene regioner på E-7-proteinet af humant papillomavirus type 16
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
NO983946L (no) Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
DE69532106D1 (de) Maltose Phospharylase, Trehalose Phophorylase, Plesiomonasstamm, und Herstellung von Trehalose
CA2237807A1 (en) Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them
DK0831899T3 (da) Rekombinant koppevirus-calicivirus-præparater og anvendelser
ATE315092T1 (de) Acetylhydrolase des plättchen aktivierenden faktors, und entsprechendes gen
ZA964094B (en) Compositions and methods for the diagnosis of and vaccination against hepatitis c virus (hcv)
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
PT1149901E (pt) Mutantes de pestivirus e vacinas contendo os mesmos
NZ330913A (en) Antigens for preventing and reducing parasite infection and disease
ATE88096T1 (de) Infektionsresistente zusammensetzungen, medizinische geraete und oberflaechen und verfahren zur herstellung und gebrauch derselben.
Waseem et al. Erratum to:'Isolation, sequence and expression of the gene encoding human keratin 13'(Gene 215 (1998) 269-279)
WO1997040166A3 (en) Simian-human hav having a chimeric 2c protein
FI893346A0 (fi) Icke-reverterande rna-virus.
ID28142A (id) Jenis virus penyebab hepatitis b vaksin dan penggunaannya
UA30385A (uk) Штам вірусу інфекційного ринотрахеїту ipt-lg /іеквм/ для виготовлення вакцини

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ACAMBIS, INC. (US) , ST. LOUIS UNIVERSITY (US)

Free format text: ALTERADO DE: ORAVAX, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 34 INCISO III DA LPI 9279/96, SOLICITA-SE, SOB PENA DE ARQUIVAMENTO DO PEDIDO, QUE A REQUERENTE APRESENTE TRADUCAO SIMPLES DOS DOIS DOCUMENTOS DE PRIORIDADE, COMPOSTOS POR NUMERO, DATA, TITULO, RELATORIO DESCRITIVO E, SE FOR O CASO, REIVINDICACOES E DESENHOS.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15V Prolongation of time limit allowed

Free format text: DEVOLUCAO DE PRAZO CONCEDIDA - RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 26 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]